[A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel]

Gan To Kagaku Ryoho. 2012 Nov;39(12):2339-41.
[Article in Japanese]

Abstract

A 54-year-old man was referred to our hospital for close examination and treatment of an advanced gastric cancer. Gastrointestinal endoscopic examination showed a type 3 tumor, which was diagnosed as well-differentiated adenocarcinoma, and computed tomography showed multiple enlarged liver metastases in both the lobes. He underwent gastrojejunostomy and was treated with S-1 and cisplatin combination chemotherapy. However, after 4 courses of chemotherapy, progression of disease occurred. Because the human epidermal growth factor receptor type 2(HER2) test was positive, we started trastuzumab and paclitaxel combination chemotherapy as a second-line treatment. After administration of 7 courses of trastuzumab and 5 courses of paclitaxel, the primary lesion and multiple liver metastases were greatly reduced. Trastuzumab and paclitaxel combination chemotherapy appears to be an effective treatment for HER2-positive advanced gastric cancer.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Gastrectomy
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Paclitaxel / administration & dosage
  • Receptor, ErbB-2 / analysis
  • Stomach Neoplasms / chemistry
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Paclitaxel